What is MiNK Therapeutics' operating income?

MiNK Therapeutics' total operating income in 2025 was -$12.64 million, based on the following breakdown: Total Gross Profit: $0.00 Total Operating Expenses: $12.64 million

MiNK Therapeutics (INKT) Financials

$10.81 -0.28 (-2.52%)

Closing price 07/16/2026 04:00 PM Eastern

Extended Trading

$10.71 -0.10 (-0.93%)

As of 04:10 AM Eastern

Compare

Annual Income Statements for MiNK Therapeutics

This table shows MiNK Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-16	-30	-28	-23	-11	-13
Consolidated Net Income / (Loss)	-16	-30	-28	-22	-11	-12
Net Income / (Loss) Continuing Operations	-16	-30	-28	-22	-11	-12
Total Pre-Tax Income	-16	-30	-28	-22	-11	-12
Total Operating Income	-15	-28	-31	-23	-11	-13
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	15	28	31	23	11	13
Selling, General & Admin Expense	1.29	4.64	7.83	7.43	4.31	6.73
Research & Development Expense	9.51	14	23	15	6.34	5.76
Other Operating Expenses / (Income)	3.84	9.75	-	-	0.64	0.15
Total Other Income / (Expense), net	-1.60	-1.85	2.96	0.46	0.50	0.15
Interest Expense	2.44	2.08	-0.25	-0.46	-0.17	-0.18
Other Income / (Expense), net	0.84	0.22	2.70	-0.00	0.33	-0.03
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	-0.33	0.14	0.20	0.09
Basic Earnings per Share	($0.67)	($1.16)	($0.83)	($6.54)	($2.86)	($2.93)
Weighted Average Basic Shares Outstanding	24.11M	26.03M	33.67M	3.44M	3.77M	4.27M
Diluted Earnings per Share	($0.67)	($1.16)	($0.83)	($6.54)	($2.86)	($2.93)
Weighted Average Diluted Shares Outstanding	24.11M	26.03M	33.67M	3.44M	3.77M	4.27M
Weighted Average Basic & Diluted Shares Outstanding	24.11M	26.03M	33.91M	34.70M	3.97M	4.97M

This table shows MiNK Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-5.03	-5.58	-3.77	-2.93	-1.87	-2.42	-2.80	-4.29	-2.86	-2.63	-2.72
Consolidated Net Income / (Loss)	-5.12	-5.46	-3.81	-2.70	-1.81	-2.46	-2.77	-4.24	-2.89	-2.60	-2.74
Net Income / (Loss) Continuing Operations	-5.12	-5.46	-3.81	-2.70	-1.81	-2.46	-2.77	-4.24	-2.89	-2.60	-2.74
Total Pre-Tax Income	-5.12	-5.46	-3.81	-2.70	-1.81	-2.46	-2.77	-4.24	-2.89	-2.60	-2.74
Total Operating Income	-5.22	-5.50	-3.83	-3.07	-1.88	-2.50	-2.70	-4.05	-3.18	-2.71	-2.88
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	5.22	5.50	3.83	3.07	1.88	2.50	2.70	4.05	3.18	2.71	2.88
Selling, General & Admin Expense	1.80	2.19	1.28	1.06	1.16	0.81	1.27	1.85	1.85	1.76	1.68
Research & Development Expense	3.43	3.31	2.55	1.84	0.54	1.41	1.26	1.84	1.14	1.51	1.20
Total Other Income / (Expense), net	0.11	0.04	0.02	0.37	0.08	0.04	-0.07	-0.19	0.30	0.10	0.14
Interest Expense	-0.11	-0.04	-0.02	-0.04	-0.08	-0.04	-0.01	-0.00	-0.06	-0.11	-0.08
Other Income / (Expense), net	0.00	-0.00	0.00	0.33	0.00	-	-0.08	-0.19	0.24	-0.01	0.06
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.09	0.12	-0.05	0.23	0.06	-0.04	0.03	0.06	-0.03	0.03	-0.02
Basic Earnings per Share	($0.15)	($1.62)	($1.10)	($0.73)	($0.46)	($0.64)	($0.70)	($1.06)	($0.65)	($0.62)	($0.57)
Weighted Average Basic Shares Outstanding	34.50M	3.44M	3.46M	3.71M	3.95M	3.77M	3.96M	3.98M	4.44M	4.27M	4.80M
Diluted Earnings per Share	($0.15)	($1.62)	($1.10)	($0.73)	($0.46)	($0.64)	($0.70)	($1.06)	($0.65)	($0.62)	($0.57)
Weighted Average Diluted Shares Outstanding	34.50M	3.44M	3.46M	3.71M	3.95M	3.77M	3.96M	3.98M	4.44M	4.27M	4.80M
Weighted Average Basic & Diluted Shares Outstanding	34.52M	34.70M	34.73M	39.54M	39.55M	3.97M	3.99M	4.52M	4.69M	4.97M	4.98M

This table details how cash moves in and out of MiNK Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	2.39	36	-19	-16	1.21	8.78
Net Cash From Operating Activities	-8.34	-13	-19	-16	-9.56	-5.93
Net Cash From Continuing Operating Activities	-8.34	-13	-19	-16	-9.56	-5.93
Net Income / (Loss) Continuing Operations	-16	-30	-28	-22	-11	-12
Consolidated Net Income / (Loss)	-16	-30	-28	-22	-11	-12
Depreciation Expense	0.06	0.08	0.12	0.20	0.22	0.18
Non-Cash Adjustments To Reconcile Net Income	8.17	14	0.24	3.59	0.55	3.10
Changes in Operating Assets and Liabilities, net	-0.32	3.74	8.77	2.90	0.46	3.29
Net Cash From Investing Activities	-0.10	-0.25	-0.25	-0.07	0.00	0.00
Net Cash From Continuing Investing Activities	-0.10	-0.25	-0.25	-0.07	0.00	0.00
Purchase of Property, Plant & Equipment	-0.10	-0.25	-0.25	-0.07	0.00	0.00
Net Cash From Financing Activities	11	49	-0.16	-0.41	11	15
Net Cash From Continuing Financing Activities	11	49	-0.16	-0.41	11	15
Repayment of Debt	11	9.46	0.00	-	5.00	0.00
Repurchase of Common Equity	-	-	-0.16	-0.48	0.00	-0.17
Issuance of Common Equity	0.00	40	0.00	0.00	5.80	14
Other Financing Activities, net	0.00	0.00	0.00	0.07	0.02	0.44
Effect of Exchange Rate Changes	-0.28	0.02	0.02	-0.03	-0.05	-0.01
Cash Interest Paid	-	0.00	0.01	0.03	0.01	0.01

This table details how cash moves in and out of MiNK Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-4.22	-3.03	2.45	3.50	-2.99	-1.75	-1.34	-1.55	13	-0.92	-3.83
Net Cash From Operating Activities	-4.21	-3.04	-2.54	-2.29	-2.99	-1.73	-1.34	-1.57	-0.94	-2.07	-1.73
Net Cash From Continuing Operating Activities	-4.21	-3.04	-2.54	-2.29	-2.99	-1.73	-1.34	-1.57	-0.94	-2.07	-1.73
Net Income / (Loss) Continuing Operations	-5.12	-5.46	-3.81	-2.70	-1.81	-2.46	-2.77	-4.24	-2.89	-2.60	-2.74
Consolidated Net Income / (Loss)	-5.12	-5.46	-3.81	-2.70	-1.81	-2.46	-2.77	-4.24	-2.89	-2.60	-2.74
Depreciation Expense	0.05	0.05	0.05	0.05	0.06	0.05	0.05	0.05	0.04	0.04	0.04
Non-Cash Adjustments To Reconcile Net Income	0.94	1.10	0.60	0.45	-1.19	0.70	0.78	1.45	0.84	0.02	0.63
Changes in Operating Assets and Liabilities, net	-0.09	1.27	0.62	-0.08	-0.06	-0.02	0.59	1.17	1.06	0.47	0.34
Net Cash From Investing Activities	-0.02	-	0.00	-	-	-	0.00	-	-	-	0.00
Net Cash From Continuing Investing Activities	-0.02	-	0.00	-	-	-	0.00	-	-	-	0.00
Purchase of Property, Plant & Equipment	-0.02	-	0.00	-	-	-	0.00	-	-	-	0.00
Net Cash From Financing Activities	0.00	-0.00	5.01	5.81	0.01	-0.00	0.00	0.00	14	1.18	-2.10
Net Cash From Continuing Financing Activities	0.00	-0.00	5.01	5.81	0.01	-0.00	0.00	0.00	14	1.18	-2.10
Repayment of Debt	-	-	-	-	-	-	0.00	-	-	-	-5.00
Repurchase of Common Equity	0.00	-0.00	0.00	-	-	-	0.00	-	-	-0.17	-0.25
Issuance of Common Equity	-	-	0.00	5.80	-	-	0.00	-	13	1.32	3.02
Other Financing Activities, net	0.00	-	0.01	0.01	0.01	-0.00	0.00	0.00	0.41	0.03	0.13
Effect of Exchange Rate Changes	0.01	0.00	-0.01	-0.02	0.00	-0.02	-0.00	0.02	-0.01	-0.02	-0.00
Cash Interest Paid	0.00	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

This table presents MiNK Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	4.56	40	21	4.55	5.72	14
Total Current Assets	4.10	40	20	3.60	4.99	14
Cash & Equivalents	2.69	39	20	3.37	4.58	13
Prepaid Expenses	0.49	0.00	0.30	0.05	0.25	0.28
Other Current Assets	0.91	0.74	0.47	0.18	0.16	0.21
Plant, Property, & Equipment, net	0.46	0.61	1.07	0.95	0.73	0.39
Total Noncurrent Assets	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities & Shareholders' Equity	4.56	40	21	4.55	5.72	14
Total Liabilities	58	16	22	23	25	28
Total Current Liabilities	14	16	13	11	6.96	13
Accounts Payable	6.67	8.94	5.82	3.91	2.73	3.43
Accrued Expenses	1.86	1.76	4.24	5.04	1.87	1.58
Other Current Liabilities	5.69	5.76	2.62	2.45	2.36	8.03
Total Noncurrent Liabilities	44	0.00	9.19	11	18	15
Long-Term Debt	44	0.00	0.00	0.00	4.92	0.00
Other Noncurrent Operating Liabilities	0.38	0.00	9.19	11	13	15
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-54	24	-0.40	-18	-20	-14
Total Preferred & Common Equity	-54	24	-0.40	-18	-20	-14
Total Common Equity	-54	24	-0.40	-18	-20	-14
Common Stock	0.38	107	111	116	125	143
Retained Earnings	-53	-83	-111	-133	-144	-157
Accumulated Other Comprehensive Income / (Loss)	-1.52	-0.63	-0.29	-0.43	-0.63	-0.72

This table presents MiNK Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	7.46	6.89	10	7.37	4.27	2.48	15	10
Total Current Assets	6.47	6.00	9.47	6.58	3.58	2.01	15	10
Cash & Equivalents	6.40	5.82	9.31	6.33	3.23	1.68	14	9.53
Prepaid Expenses	0.04	0.06	0.10	0.24	0.24	0.27	0.25	0.26
Other Current Assets	0.03	0.12	0.06	0.01	0.11	0.06	0.00	0.23
Plant, Property, & Equipment, net	0.99	0.89	0.85	0.80	0.69	0.47	0.43	0.35
Total Noncurrent Assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities & Shareholders' Equity	7.46	6.89	10	7.37	4.27	2.48	15	10
Total Liabilities	21	27	27	25	26	28	28	23
Total Current Liabilities	10	11	10	7.40	12	13	13	7.29
Accounts Payable	4.28	3.49	3.20	2.36	2.66	3.31	3.69	3.39
Accrued Expenses	3.85	5.28	4.63	2.65	1.97	1.86	1.26	1.33
Other Current Liabilities	2.27	2.34	2.32	2.39	7.49	7.99	8.48	2.57
Total Noncurrent Liabilities	11	16	17	18	14	15	15	16
Long-Term Debt	-	4.21	4.41	4.61	0.00	0.00	0.00	0.00
Other Noncurrent Operating Liabilities	11	12	12	13	14	15	15	16
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-14	-20	-17	-18	-22	-25	-14	-13
Total Preferred & Common Equity	-14	-20	-17	-18	-22	-25	-14	-13
Total Common Equity	-14	-20	-17	-18	-22	-25	-14	-13
Common Stock	115	117	124	125	126	127	141	147
Retained Earnings	-128	-137	-140	-142	-147	-151	-154	-159
Accumulated Other Comprehensive Income / (Loss)	-0.31	-0.39	-0.61	-0.67	-0.66	-0.72	-0.69	-0.70

This table displays calculated financial ratios and metrics derived from MiNK Therapeutics' official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	33,504,350.00	33,775,073.00	34,519,540.00	39,549,975.00	4,694,155.00
DEI Adjusted Shares Outstanding	0.00	3,350,435.00	3,377,507.00	3,451,954.00	3,954,997.00	4,694,155.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-9.02	-8.19	-6.55	-2.78	-2.68
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	-104.17%	-0.23%	19.22%	52.71%	-16.30%
EBIT Growth	0.00%	-103.92%	-0.38%	18.85%	52.20%	-15.67%
NOPAT Growth	0.00%	-93.74%	-9.14%	25.94%	50.75%	-11.99%
Net Income Growth	0.00%	-86.05%	7.35%	19.77%	51.98%	-15.85%
EPS Growth	0.00%	-73.13%	28.45%	19.77%	51.98%	-2.45%
Operating Cash Flow Growth	0.00%	-53.84%	-47.09%	16.45%	39.38%	37.99%
Free Cash Flow Firm Growth	0.00%	0.00%	4.23%	12.43%	31.20%	95.04%
Invested Capital Growth	0.00%	-18.61%	-32.59%	-6.92%	10.20%	-43.40%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	9.63%	21.82%	-1.84%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	9.49%	21.48%	-1.69%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	9.44%	20.98%	-1.63%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	9.33%	21.74%	-1.13%
EPS Q/Q Growth	0.00%	0.00%	0.00%	9.33%	21.74%	-5.02%
Operating Cash Flow Q/Q Growth	0.00%	0.12%	0.00%	8.13%	12.04%	-6.20%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	-747.92%	5.82%	-171.58%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-7.22%	0.17%	0.74%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	117.69%	107.38%	99.10%	97.98%	98.43%	98.58%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	30.14%	200.76%	-239.50%	243.36%	57.30%	73.90%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	30.14%	200.76%	-239.50%	243.36%	57.30%	73.90%
Return on Equity Simple (ROE_SIMPLE)	30.14%	-127.07%	0.00%	124.38%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-10	-20	-22	-16	-7.90	-8.85
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	14.57%	923.50%	-21.62%	-55.76%	-190.95%	-56.02%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	88.86%	53.90%	62.20%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-14	-28	-28	-23	-11	-13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-14	-28	-28	-23	-11	-12
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	6.28	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	6.28	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	-0.81	0.00	0.00	0.00	-0.25	0.00
Long-Term Debt to Equity	-0.81	0.00	0.00	0.00	-0.25	0.00
Financial Leverage	-0.76	-0.07	-2.50	1.25	0.08	0.38
Leverage Ratio	-0.08	-1.49	2.64	-1.41	-0.27	-0.59
Compound Leverage Factor	-0.10	-1.60	2.62	-1.38	-0.27	-0.58
Debt to Total Capital	-436.05%	0.00%	0.00%	0.00%	-33.59%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	-436.05%	0.00%	0.00%	0.00%	-33.59%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	536.05%	100.00%	100.00%	100.00%	133.59%	100.00%
Debt to EBITDA	-3.19	0.00	0.00	0.00	-0.46	0.00
Net Debt to EBITDA	-2.99	0.00	0.00	0.00	-0.03	0.00
Long-Term Debt to EBITDA	-3.19	0.00	0.00	0.00	-0.46	0.00
Debt to NOPAT	-4.28	0.00	0.00	0.00	-0.62	0.00
Net Debt to NOPAT	-4.01	0.00	0.00	0.00	-0.04	0.00
Long-Term Debt to NOPAT	-4.28	0.00	0.00	0.00	-0.62	0.00
Altman Z-Score	-28.46	0.94	-8.72	-58.72	-41.37	-17.17
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.29	2.41	1.61	0.32	0.72	1.06
Quick Ratio	0.19	2.36	1.55	0.30	0.66	1.03
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-17	-17	-15	-10	-0.50
Operating Cash Flow to CapEx	-8,757.06%	-5,151.80%	-7,545.35%	-21,427.81%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-8.42	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-3.42	-6.18	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-3.45	-6.30	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	-13	-15	-20	-21	-19	-28
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	-2.37	-4.92	-1.39	2.18	-8.35
Enterprise Value (EV)	81	111	69	34	28	39
Market Capitalization	40	149	88	37	28	52
Book Value per Share	($2.23)	$0.71	($0.01)	($0.52)	($0.50)	($3.03)
Tangible Book Value per Share	($2.23)	$0.71	($0.01)	($0.52)	($0.50)	($3.03)
Total Capital	-10	24	-0.40	-18	-15	-14
Total Debt	44	0.00	0.00	0.00	4.92	0.00
Total Long-Term Debt	44	0.00	0.00	0.00	4.92	0.00
Net Debt	41	-39	-20	-3.37	0.35	-13
Capital Expenditures (CapEx)	0.10	0.25	0.25	0.07	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-13	-16	-12	-11	-6.55	-13
Debt-free Net Working Capital (DFNWC)	-10	23	7.72	-7.80	-1.97	0.82
Net Working Capital (NWC)	-10	23	7.72	-7.80	-1.97	0.82
Net Nonoperating Expense (NNE)	5.99	10	6.33	6.41	2.88	3.64
Net Nonoperating Obligations (NNO)	41	-39	-20	-3.37	0.35	-13
Total Depreciation and Amortization (D&A)	0.06	0.08	0.12	0.20	0.22	0.18
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($1.16)	($0.83)	($6.50)	($2.86)	($2.93)
Adjusted Weighted Average Basic Shares Outstanding	0.00	33.56M	33.67M	3.44M	3.77M	4.27M
Adjusted Diluted Earnings per Share	$0.00	($1.16)	($0.83)	($6.50)	($2.86)	($2.93)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	33.56M	33.67M	3.44M	3.77M	4.27M
Adjusted Basic & Diluted Earnings per Share	$0.00	($1.16)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	26.03M	33.91M	3.47M	3.97M	4.97M
Normalized Net Operating Profit after Tax (NOPAT)	-10	-20	-22	-16	-7.90	-8.85
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-5.65	-13.55	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-4.20	-9.56	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-5.69	-13.67	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-4.24	-9.68	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.56%	-2.13%	0.00%	-1.39%

This table displays calculated financial ratios and metrics derived from MiNK Therapeutics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	34,508,336.00	34,519,540.00	34,699,056.00	34,727,639.00	39,539,689.00	39,549,975.00	3,966,392.00	3,985,657.00	4,522,927.00	4,694,155.00	4,965,858.00
DEI Adjusted Shares Outstanding	3,450,834.00	3,451,954.00	3,469,906.00	3,472,764.00	3,953,969.00	3,954,997.00	3,966,392.00	3,985,657.00	4,522,927.00	4,694,155.00	4,965,858.00
DEI Earnings Per Adjusted Shares Outstanding	-1.46	-1.62	-1.09	-0.84	-0.47	-0.61	-0.71	-1.08	-0.63	-0.56	-0.55
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	19.17%	30.76%	34.99%	57.16%	64.76%	55.04%	27.72%	-55.44%	-59.12%	-9.23%	-2.11%
EBIT Growth	18.69%	30.42%	34.58%	56.80%	63.92%	54.50%	27.41%	-54.67%	-56.15%	-8.42%	-1.55%
NOPAT Growth	34.60%	30.28%	34.58%	51.59%	63.92%	54.50%	29.48%	-31.95%	-68.93%	-8.10%	-6.71%
Net Income Growth	19.20%	29.75%	32.94%	56.40%	64.69%	54.88%	27.45%	-56.85%	-59.84%	-5.64%	0.88%
EPS Growth	21.05%	29.75%	32.94%	56.40%	64.69%	54.88%	36.36%	-45.21%	-41.30%	3.13%	18.57%
Operating Cash Flow Growth	25.03%	31.48%	41.78%	44.82%	28.85%	43.09%	47.26%	31.50%	68.57%	-20.03%	-29.21%
Free Cash Flow Firm Growth	197.87%	-312.26%	180.95%	-63.21%	-112.43%	-59.72%	-87.14%	425.64%	410.37%	264.01%	-492.40%
Invested Capital Growth	0.00%	-6.92%	-127.05%	-6.79%	3.55%	10.20%	-14.25%	-25.07%	-44.23%	-43.40%	11.25%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	17.82%	-5.35%	30.67%	28.63%	32.40%	-34.40%	-11.46%	-53.49%	30.80%	7.74%	-4.20%
EBIT Q/Q Growth	17.65%	-5.29%	30.37%	28.45%	31.22%	-32.80%	-11.09%	-52.44%	30.56%	7.80%	-4.05%
NOPAT Q/Q Growth	17.65%	-5.29%	30.37%	19.81%	38.63%	-32.80%	-7.91%	-50.05%	21.44%	15.02%	-6.52%
Net Income Q/Q Growth	17.44%	-6.69%	30.14%	29.15%	33.13%	-36.34%	-12.33%	-53.17%	31.86%	9.89%	-5.39%
EPS Q/Q Growth	16.67%	-6.69%	30.14%	29.15%	33.13%	-36.34%	-9.38%	-51.43%	38.68%	4.62%	8.06%
Operating Cash Flow Q/Q Growth	-1.40%	27.87%	16.26%	9.89%	-30.74%	42.31%	22.39%	-17.03%	40.01%	-120.29%	16.45%
Free Cash Flow Firm Q/Q Growth	3,501.59%	-115.10%	488.58%	-108.18%	-158.96%	-94.08%	131.29%	107.10%	146.82%	2.56%	-174.85%
Invested Capital Q/Q Growth	0.69%	-7.22%	-2.25%	1.92%	10.30%	0.17%	-30.09%	-7.37%	-3.43%	0.74%	19.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	97.95%	99.25%	99.57%	98.60%	95.86%	98.42%	99.51%	99.99%	98.13%	95.90%	97.14%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	364.77%	243.36%	166.18%	131.10%	88.52%	57.30%	46.27%	53.99%	79.54%	73.90%	72.34%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	364.77%	243.36%	166.18%	131.10%	88.52%	57.30%	46.27%	53.99%	79.54%	73.90%	72.34%
Return on Equity Simple (ROE_SIMPLE)	182.38%	0.00%	101.41%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.66	-3.85	-2.68	-2.15	-1.32	-1.75	-1.89	-2.84	-2.23	-1.89	-2.02
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-45.63%	-13.99%	-33.42%	-7.11%	-12.01%	-47.11%	-36.20%	-42.52%	-8.24%	-10.89%	-11.37%
Return On Investment Capital (ROIC_SIMPLE)	-	21.32%	16.66%	17.66%	10.19%	11.95%	8.68%	11.26%	16.49%	13.31%	15.90%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-5.22	-5.50	-3.83	-2.74	-1.88	-2.50	-2.78	-4.24	-2.94	-2.71	-2.82
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-5.17	-5.45	-3.78	-2.70	-1.82	-2.45	-2.73	-4.19	-2.90	-2.67	-2.79
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	13.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	-0.21	-0.27	-0.26	-0.25	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	-0.21	-0.27	-0.26	-0.25	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.47	1.25	0.27	0.60	0.26	0.08	0.12	0.16	0.51	0.38	0.37
Leverage Ratio	-0.55	-1.41	-0.95	-0.86	-0.48	-0.27	-0.27	-0.31	-0.72	-0.59	-0.42
Compound Leverage Factor	-0.54	-1.40	-0.94	-0.85	-0.46	-0.27	-0.26	-0.31	-0.71	-0.57	-0.41
Debt to Total Capital	0.00%	0.00%	-26.18%	-36.20%	-35.63%	-33.59%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	-26.18%	-36.20%	-35.63%	-33.59%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	126.18%	136.20%	135.63%	133.59%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	-0.20	-0.26	-0.34	-0.46	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.08	0.29	0.12	-0.03	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	-0.20	-0.26	-0.34	-0.46	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	-0.29	-0.36	-0.46	-0.62	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.11	0.40	0.17	-0.04	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	-0.29	-0.36	-0.46	-0.62	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-25.86	-46.09	-29.89	-19.19	-27.17	-36.49	-51.97	-95.57	-13.64	-14.86	-20.73
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.62	0.32	0.54	0.93	0.89	0.72	0.30	0.15	1.08	1.06	1.38
Quick Ratio	0.62	0.30	0.52	0.92	0.86	0.66	0.27	0.13	1.06	1.03	1.31
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	16	-2.46	9.58	-0.78	-2.03	-3.94	1.23	2.55	6.29	6.46	-4.83
Operating Cash Flow to CapEx	-18,266.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-20	-21	-22	-21	-19	-19	-25	-27	-28	-28	-22
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-20	-1.39	-12	-1.37	0.71	2.18	-3.12	-5.39	-8.52	-8.35	2.82
Enterprise Value (EV)	32	34	30	28	28	28	31	28	49	39	43
Market Capitalization	38	37	32	33	30	28	34	29	63	52	52
Book Value per Share	($0.39)	($0.52)	($0.59)	($0.48)	($0.44)	($0.50)	($5.49)	($6.32)	($2.99)	($3.03)	($2.70)
Tangible Book Value per Share	($0.39)	($0.52)	($0.59)	($0.48)	($0.44)	($0.50)	($5.49)	($6.32)	($2.99)	($3.03)	($2.70)
Total Capital	-14	-18	-16	-12	-13	-15	-22	-25	-14	-14	-13
Total Debt	0.00	0.00	4.21	4.41	4.61	4.92	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	4.21	4.41	4.61	4.92	0.00	0.00	0.00	0.00	0.00
Net Debt	-6.40	-3.37	-1.61	-4.91	-1.72	0.35	-3.23	-1.68	-14	-13	-9.53
Capital Expenditures (CapEx)	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-10	-11	-11	-9.99	-7.15	-6.55	-12	-13	-13	-13	-6.79
Debt-free Net Working Capital (DFNWC)	-3.92	-7.80	-5.11	-0.67	-0.82	-1.97	-8.54	-11	1.10	0.82	2.74
Net Working Capital (NWC)	-3.92	-7.80	-5.11	-0.67	-0.82	-1.97	-8.54	-11	1.10	0.82	2.74
Net Nonoperating Expense (NNE)	1.46	1.61	1.13	0.55	0.49	0.71	0.88	1.40	0.66	0.71	0.73
Net Nonoperating Obligations (NNO)	-6.40	-3.37	-1.61	-4.91	-1.72	0.35	-3.23	-1.68	-14	-13	-9.53
Total Depreciation and Amortization (D&A)	0.05	0.05	0.05	0.05	0.06	0.05	0.05	0.05	0.04	0.04	0.04
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.15)	($16.20)	($1.10)	($0.70)	($0.50)	($6.40)	($0.70)	($1.06)	($0.65)	($0.62)	($0.57)
Adjusted Weighted Average Basic Shares Outstanding	34.50M	343.60K	3.46M	3.71M	3.95M	377.33K	3.96M	3.98M	4.44M	4.27M	4.80M
Adjusted Diluted Earnings per Share	($0.15)	($16.20)	($1.10)	($0.70)	($0.50)	($6.40)	($0.70)	($1.06)	($0.65)	($0.62)	($0.57)
Adjusted Weighted Average Diluted Shares Outstanding	34.50M	343.60K	3.46M	3.71M	3.95M	377.33K	3.96M	3.98M	4.44M	4.27M	4.80M
Adjusted Basic & Diluted Earnings per Share	$0.00	($16.20)	$0.00	$0.00	$0.00	($6.40)	$0.00	$0.00	$0.00	($0.62)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	34.52M	3.47M	3.47M	3.95M	3.95M	396.64K	3.99M	4.52M	4.69M	4.97M	4.98M
Normalized Net Operating Profit after Tax (NOPAT)	-3.66	-3.85	-2.68	-2.15	-1.32	-1.75	-1.89	-2.84	-2.23	-1.89	-2.02
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-1.93%	-2.13%	-0.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.39%	-3.41%

Financials Breakdown Chart

MiNK Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, MiNK Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

MiNK Therapeutics' net income appears to be on a downward trend, with a most recent value of -$12.49 million in 2025, falling from -$16.24 million in 2020. The previous period was -$10.78 million in 2024. View MiNK Therapeutics' forecast to see where analysts expect MiNK Therapeutics to go next.

MiNK Therapeutics' total operating income in 2025 was -$12.64 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $12.64 million

Over the last 5 years, MiNK Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

MiNK Therapeutics' total liabilities were at $28.47 million at the end of 2025, a 12.5% increase from 2024, and a 51.3% decrease since 2020.

In the past 5 years, MiNK Therapeutics' cash and equivalents has ranged from $2.69 million in 2020 to $38.89 million in 2021, and is currently $13.36 million as of their latest financial filing in 2025.

Over the last 5 years, MiNK Therapeutics' book value per share changed from -2.23 in 2020 to -3.03 in 2025, a change of 35.6%.

Related Companies

Financial statements for NASDAQ:INKT last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiNK Therapeutics (INKT) Financials

Financials Breakdown Chart

MiNK Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiNK Therapeutics (INKT) Financials

Annual Income Statements for MiNK Therapeutics

Quarterly Income Statements for MiNK Therapeutics

Annual Cash Flow Statements for MiNK Therapeutics

Quarterly Cash Flow Statements for MiNK Therapeutics

Annual Balance Sheets for MiNK Therapeutics

Quarterly Balance Sheets for MiNK Therapeutics

Annual Metrics And Ratios for MiNK Therapeutics

Quarterly Metrics And Ratios for MiNK Therapeutics

Financials Breakdown Chart

MiNK Therapeutics Financials - Frequently Asked Questions

When does MiNK Therapeutics' fiscal year end?

How has MiNK Therapeutics' net income changed over the last 5 years?

What is MiNK Therapeutics' operating income?

How has MiNK Therapeutics' revenue changed over the last 5 years?

How much debt does MiNK Therapeutics have?

How much cash does MiNK Therapeutics have?

How has MiNK Therapeutics' book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools